title: Narrow-band ultraviolet B treatment boosts serum 25-hydroxyvitamin D in patients with psoriasis on oral vitamin D supplementation.
abstract: A course of treatment with narrow-band ultraviolet B (NB-UVB) improves psoriasis and increases serum 25-hydroxyvitamin D (25(OH)D). In this study 12 patients with psoriasis who were supplemented with oral cholecalciferol, 20 µg daily, were given a course of NB-UVB and their response measured. At baseline, serum 25(OH)D was 74.14 ± 22.9 nmol/l. At the 9th exposure to NB-UVB 25(OH)D had increased by 13.2 nmol/l (95% confidence interval (95% CI) 7.2-18.4) and at the 18th exposure by 49.4 nmol/l (95% CI 35.9-64.6) above baseline. Psoriasis Area Severity Index score improved from 8.7 ± 3.5 to 4.5 ± 2.0 (p < 0.001). At baseline, psoriasis lesions showed low vitamin D metabolizing enzyme (CYP27A1, CYP27B1) and high human β-defensin-2 mRNA expression levels compared with those of the healthy subjects. In conclusion, NB-UVB treatment significantly increases serum 25(OH)D in patients with psoriasis who are taking oral vitamin D supplementation, and the concentrations remain far from the toxicity level. Healing psoriasis lesions show similar mRNA expression of vitamin D metabolizing enzymes, but higher antimicrobial peptide levels than NB-UVB-treated skin in healthy subjects.
authors.affiliation: Department of Dermatology, Tampere University Hospital, FIN-33521 Tampere, Finland.
authors.forename: Meri J
authors.initials: MJ
authors.lastname: Ala-Houhala
authors.forename: Toni
authors.initials: T
authors.lastname: Karppinen
authors.forename: Katja
authors.initials: K
authors.lastname: Vähävihu
authors.forename: Hannu
authors.initials: H
authors.lastname: Kautiainen
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Dombrowski
authors.forename: Erna
authors.initials: E
authors.lastname: Snellman
authors.forename: Jürgen
authors.initials: J
authors.lastname: Schauber
authors.forename: Timo
authors.initials: T
authors.lastname: Reunala
mesh_terms: D015090:25-Hydroxyvitamin D3 1-alpha-Hydroxylase / Q000235:genetics / Q000378:metabolism; D000284:Administration, Oral; D000328:Adult; D001706:Biopsy; D002762:Cholecalciferol / Q000627:therapeutic use; D053493:Cholestanetriol 26-Monooxygenase / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000097:blood* / Q000378:metabolism / Q000628:therapy*; D012333:RNA, Messenger / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D012867:Skin / Q000378:metabolism / Q000473:pathology; D014467:Ultraviolet Therapy; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000097:blood; D014808:Vitamin D Deficiency / Q000628:therapy; D014815:Vitamins / Q000627:therapeutic use; D023083:beta-Defensins / Q000235:genetics / Q000378:metabolism
chemical_list: C106641:DEFB4A protein, human; D012333:RNA, Messenger; D014815:Vitamins; D023083:beta-Defensins; D014807:Vitamin D; D002762:Cholecalciferol; C104450:25-hydroxyvitamin D; C506831:CYP27A1 protein, human; D053493:Cholestanetriol 26-Monooxygenase; D015090:25-Hydroxyvitamin D3 1-alpha-Hydroxylase